Farma

Nor96
18.12.2018 kl 22:22 1989

BerGenBio ASA: Notice of Arbitration with Rigel Pharmaceuticals, Inc.

Bergen, Norway, 13 September 2018 - BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, today served Notice of Arbitration to Rigel Pharmaceuticals, Inc. pursuant to a License Agreement made and entered into as of 29 June 2011.

A dispute has arisen between the Parties with respect to the interpretation and application of certain provisions of the Agreement, particularly as they relate to the rights and obligations of the parties in the event of the licensing or sale of a Product(s) by BerGenBio and/or the sale of BerGenBio to a third party.

The Parties agreed to a binding arbitration before a panel of three (3) arbitrators in Toronto, Canada pursuant to the then-current Canadian Arbitration Association rules, to be completed with 180 days of commencement.

- Ends -
Publisert OSE

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.